R&D FDA’s emerging framework to reduce animal testing: Implicati... Exploring the strategic shift toward reducing reliance on non-human primates (NHPs) and other animal species in R&D.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
